Clinical Trial Detail

NCT ID NCT04043195
Title Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hatim Husain
Indications

lung squamous cell carcinoma

lung non-squamous non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab + Oxaliplatin

Nivolumab + Oxaliplatin

Age Groups: adult senior

No variant requirements are available.